Search our Database of Scientific Publications and Authors

I’m looking for a

    3535 results match your criteria Plaque Psoriasis

    1 OF 71

    Biological therapies in psoriasis - revisited.
    Rom J Intern Med 2017 Nov 27. Epub 2017 Nov 27.
    .
    Psoriasis is a chronic, immune mediated disorder affecting approximately 2% of the population. Even in our days, patients with psoriasis are confronted with stigmatization and social rejection. As a result, their quality of life is significantly impaired. Read More

    A Phase I Randomised Controlled Trial to Evaluate Safety and Clinical Effect of Topically Applied GSK2981278 Ointment in a Psoriasis Plaque Test.
    Br J Dermatol 2017 Nov 18. Epub 2017 Nov 18.
    GlaxoSmithKline, Collegeville, PA, USA.
    RORγt, a truncated isoform of retinoic acid receptor-related orphan receptor gamma (RORγ), is a transcription factor involved in Th17 cell differentiation. It is expressed in a few distinct types of immune cells and described as the master regulator of Th17 cytokine expression(1) . RORγ has identical ligand-binding domains as RORγt(2) ; consequently, compounds targeting RORγ are also expected to modulate Th17 cell activity. Read More

    [Psoriatic arthritis in France, from infants to the elderly: Findings from two cross-sectional, multicenter studies].
    Ann Dermatol Venereol 2017 Nov 13. Epub 2017 Nov 13.
    Service de dermatologie et médecine vasculaire, hôpital Victor-Dupouy, 69, rue du Lieutenant-Colonel-Prud'hon, 95100 Argenteuil, France. Electronic address:
    Background: Psoriatic arthritis affects 20-30% of patients with psoriasis. Few epidemiological data are available in France about its prevalence and its association with skin lesions and comorbidities.

    Objectives: To assess the epidemiological aspects and the risk factors for psoriatic arthritis in children and adults in France. Read More

    TNF Antagonists: Killing Two "Birds" with one Biologic "Stone".
    Arthritis Rheumatol 2017 Nov 16. Epub 2017 Nov 16.
    Division of Rheumatology, Department of Medicine of the Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
    Forty years have passed since it was first recognized that patients with autoimmune rheumatic disease have an increased risk of fatal and non-fatal cardiovascular (CV) events (1) Although initial reports focused on rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), similar findings were verified subsequently in patients with psoriasis (Ps) and/or psoriatic arthritis (PsA) and spondyloarthritis. An early feature of the atherosclerotic lesion is infiltration with inflammatory cells, particularly monocytes/macrophages, and the presence of these cells in mature plaque elevates the risk of plaque rupture and thrombosis (2). In the general population, modest elevations of circulating inflammatory proteins, including C-reactive protein (CRP), interleukin-6 (IL-6) and soluble endothelial adhesion proteins, are associated with an increased risk of acute CV events (3). Read More

    The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
    Dermatol Ther (Heidelb) 2017 Dec 15;7(4):425-446. Epub 2017 Nov 15.
    Department of Dermatology, University of California San Francisco, San Francisco, USA.
    Introduction: Palmoplantar psoriasis (PP) and palmoplantar pustulosis (PPP) are diseases affecting the hands and/or feet that can cause marked physical discomfort and functional disability. The tumor necrosis factor-alpha antagonists adalimumab, etanercept, and infliximab, the interleukin (IL)-17A inhibitors ixekizumab and secukinumab, and the IL-23 or IL-12/IL-23 inhibitors guselkumab and ustekinumab have been well studied for the treatment of moderate to severe plaque psoriasis. Less is known about the efficacy and safety of these agents for the treatment of PP (hyperkeratotic and pustular forms) and PPP. Read More

    Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
    J Eur Acad Dermatol Venereol 2017 Nov 14. Epub 2017 Nov 14.
    Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.
    The effects of tofacitinib in treating moderate-to-severe plaque psoriasis were unclear. We aimed to assess the effects of tofacitinib in treating moderate-to-severe plaque psoriasis. We searched PubMed, Cochrane Central Register of Controlled Trials, and EMBASE for relevant randomised controlled trials (RCTs), and conducted a systematic review and meta-analysis. Read More

    Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials.
    Ann Pharmacother 2017 Nov 1:1060028017743268. Epub 2017 Nov 1.
    1 Wake Forest School of Medicine, Winston-Salem, NC, USA.
    Objective: Guselkumab, an anti-interleukin-23 monoclonal antibody was recently approved for the treatment of patients with moderate-to-severe plaque psoriasis. This article will review the available phase II and phase III guselkumab clinical trial data.

    Data Sources: A PubMed search was conducted using the terms guselkumab, interleukin-23, psoriasis, adalimumab, and ustekinumab (January 2014 to August 2017). Read More

    DFD-01 Reduces Transepidermal Water Loss and Improves Skin Hydration and Flexibility.
    Dermatol Ther (Heidelb) 2017 Dec 13;7(4):507-514. Epub 2017 Nov 13.
    cyberDERM Clinical Studies, Broomall, PA, USA.
    Introduction: In plaque psoriasis, the benefit of topical steroids is well established. The vehicle formulation of topical steroids may also provide benefit in addition to the effects of the steroid itself. DFD-01 (betamethasone dipropionate spray, 0. Read More

    Change of Oral to Topical Corticosteroid Therapy Exacerbated Glucose Tolerance in a Patient with Plaque Psoriasis.
    Am J Case Rep 2017 Nov 13;18:1198-1203. Epub 2017 Nov 13.
    Department of Internal Medicine, Saga University Hospital, Saga City, Saga, Japan.
    BACKGROUND Psoriasis is known as the most frequent disease treated by long-term topical steroids. It is also known that patients with thick, chronic plaques require the highest potency topical steroids. However, the treatment is limited to up to four weeks due to risk of systemic absorption. Read More

    Fumaric acid esters in combination with a 6-week course of narrow-band UVB provides for an accelerated response as compared to fumaric acid esters monotherapy in patients with moderate to severe plaque psoriasis: A randomized prospective clinical study.
    Br J Dermatol 2017 Nov 8. Epub 2017 Nov 8.
    Department of Dermatology, Division of General Dermatology and Dermato-Oncology, Medical University of Vienna, Austria.
    Background: Fumaric acid esters are (FAE) safe and effective in patients with moderate to severe psoriasis but have a slow onset of action. A short-term combination with narrow-band UVB (NB UVB) may substantially accelerate the therapeutic response in the induction phase of treatment.

    Objectives: To assess the synergistic effect of a 6-week course of NB UVB phototherapy in addition to fumaric acid esters in adult patients with moderate to severe plaque psoriasis. Read More

    Pharmacokinetics, Immunogenicity, and Efficacy of Etanercept in Pediatric Patients With Moderate to Severe Plaque Psoriasis.
    J Clin Pharmacol 2017 Nov 6. Epub 2017 Nov 6.
    Northwestern University Feinberg School of Medicine and the Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
    Etanercept has been recently approved in the United States for the treatment of moderate to severe plaque psoriasis in patients aged 4-17 years. The objective of this study was to characterize etanercept pharmacokinetics, immunogenicity, and efficacy in pediatric patients. Data from a phase 3 study and open-label extension study were analyzed. Read More

    Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.
    Health Technol Assess 2017 Nov;21(64):1-244
    Centre for Health Economics, University of York, York, UK.
    Background: Psoriasis is a chronic inflammatory disease that predominantly affects the skin. Adalimumab (HUMIRA(®), AbbVie, Maidenhead, UK), etanercept (Enbrel(®), Pfizer, New York, NY, USA) and ustekinumab (STELARA(®), Janssen Biotech, Inc., Titusville, NJ, USA) are the three biological treatments currently licensed for psoriasis in children. Read More

    A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents.
    Expert Opin Biol Ther 2017 Nov 6:1-14. Epub 2017 Nov 6.
    a Dermatology Department , University of Pisa , Pisa , Italy.
    Introduction: Psoriasis is a chronic inflammatory skin disease whose pathogenesis is driven by multiple cytokine-mediated pathways. In this immunologic setting, the centrality of the IL-23/IL-17 axis and its therapeutic relevance has emerged. Areas covered: This review is aimed at collecting preliminary data on IL23p19 blockers developed for the treatment of plaque psoriasis. Read More

    Safety, efficacy, and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.
    Br J Dermatol 2017 Nov 1. Epub 2017 Nov 1.
    Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
    Background: Real-life data on newer biologic and biosimilar agents for moderate-to-severe psoriasis are lacking.

    Objectives: To examine safety, efficacy, and time to discontinuation (drug survival) of biologics (adalimumab, etanercept, infliximab, secukinumab, and ustekinumab) and compare originators with biosimilars (i.e. Read More

    Tofacitinib: A New Oral Therapy for Psoriasis.
    Clin Drug Investig 2017 Nov 1. Epub 2017 Nov 1.
    Department of Dermatology, Centro Hospitalar do Porto, Rua D. Manuel II, S/N, ex-CICAP, 4099-001, Porto, Portugal.
    Psoriasis is a common, chronic, immune-mediated disease associated with several comorbidities. Biologic therapy revolutionized the treatment of moderate-to-severe psoriasis, improving physical and emotional burden of the disease. Still, there are unmet needs in the treatment of psoriasis regarding long-term efficacy, tolerability, safety, route of administration, and cost. Read More

    Expression of Th1 and Th2 Cytokine and Associated Transcription Factors in Peripheral Blood Mononuclear Cells and Correlation with Disease Severity.
    Rep Biochem Mol Biol 2017 Oct;6(1):102-111
    Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
    Background: Psoriasis is a T cell-mediated autoimmune disease in patients with elevated levels of proinflammatory cytokines belonging mainly to the Th1 pathway. We investigated whether treatment of psoriasis patients with methotrexate (MTX), along with micronutrients, modulated mRNA expression of Th1 and Th2 components and whether expression of these components correlated with psoriasis severity.

    Methods: Thirty plaque-type psoriasis patients with Psoriasis Area and Severity Index (PASI) scores greater than 10 were recruited; these were 15 non-micronutrients taking- (NMT) patients treated with MTX daily (0. Read More

    [The positive relationship between survivin and STAT2 up-expressed in skin lesions of psoriasis vulgaris].
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2017 Sep;33(9):1261-1265
    Department of Dermatology, Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an 710004, China.
    Objective To investigate the expressions of the inhibitor of apoptosis protein survivin and signal transducer and activator of transcription 2 (STAT2) in the tissues of the plaque-like lesions of patients with psoriasis vulgaris (PV) in the progressive stage and discuss their correlation. Methods We collected the plaque-like lesion samples and non-lesion samples from 22 PV patients and the normal skin sample from 18 healthy controls. Real-time quantitative PCR was used to evaluate the mRNA levels of survivin and STAT2 in these samples. Read More

    TNF-α inhibitors are associated with reduced indices of subclinical atherosclerosis in patients with psoriatic disease.
    Arthritis Rheumatol 2017 Oct 31. Epub 2017 Oct 31.
    National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, US.
    Objectives: We performed a two-stage study to assess the effect of TNF-α inhibitors (TNFi) on subclinical cardiovascular disease in psoriatic patients.

    Methods: We first assessed carotid total plaque area by ultrasound at baseline and after 2-3 years in patients with psoriasis and psoriatic arthritis (PsA) (n=319). The annual progression rate of atherosclerosis was the outcome of interest. Read More

    Low incidence of hypercalcemia following combined calcipotriol hydrate/betamethasone dipropionate ointment treatment in Japanese patients with severe psoriasis vulgaris.
    J Dermatolog Treat 2017 Oct 27:1-16. Epub 2017 Oct 27.
    a Department of Geriatric and Environmental Dermatology , Nagoya City University Graduate School of Medical Sciences , Nagoya , Japan.
    Purpose: Topical active vitamin D3 application alone or in combination with topical steroid application is widely used to treat psoriasis. In Japan, combined calcipotriol hydrate/betamethasone dipropionate ointment has been used for patients with psoriasis vulgaris since September 2014. Current evidence regarding the incidence of hypercalcemia due to the use of this combination product, however, is insufficient. Read More

    Patients' Perspectives on the Impact of Genital Psoriasis: A Qualitative Study.
    Dermatol Ther (Heidelb) 2017 Dec 26;7(4):447-461. Epub 2017 Oct 26.
    Dawes Fretzin Dermatology Group, Indianapolis, IN, USA.
    Introduction: Plaque psoriasis is a chronic skin disease where genital involvement is relatively common. Yet health care providers do not routinely evaluate psoriasis patients for genital involvement and patients do not readily initiate discussion of it.

    Methods: A qualitative study of 20 US patients with dermatologist-confirmed genital psoriasis (GenPs) and self-reported moderate-to-severe GenPs at screening was conducted to identify key GenPs symptoms and their impacts on health-related quality of life (HRQoL). Read More

    The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment.
    Adv Clin Exp Med 2017 Aug;26(5):851-856
    Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Poland.
    Background: A wide variety of psoriasis assessment tools have been proposed to evaluate the severity of psoriasis in clinical trials and daily practice. The most frequently used clinical instrument is the psoriasis area and severity index (PASI); however, none of the currently published severity scores used for psoriasis meets all the validation criteria required for an ideal score.

    Objectives: The aim of this study was to compare and assess the reliability of 3 commonly used assessment instruments for psoriasis severity: the psoriasis area and severity index (PASI), body surface area (BSA) and physician global assessment (PGA). Read More

    Polymorphism of glutathione S-transferase M1 and T1 genes and susceptibility to psoriasis disease: A study from North India.
    Indian J Dermatol Venereol Leprol 2017 Oct 23. Epub 2017 Oct 23.
    Department of Genetics, M.D. University, Rohtak, Haryana, India.
    Background: Increased oxidative stress and resulting inflammation has been emphasized as a factor in the pathogenesis of many diseases including psoriasis. Glutathione S-transferases (GSTs) protect against oxidative stress, inflammation, and genotoxicity. Polymorphisms in the GST genes may lead to an imbalance in pro- and antioxidant systems resulting in the increased production of reactive oxygen species that could influence the pathogenesis of psoriasis. Read More

    A clinical review of phototherapy for psoriasis.
    Lasers Med Sci 2017 Oct 24. Epub 2017 Oct 24.
    Wellman Center for Photomedicine, Massachusetts General Hospital, and Department of Dermatology, Harvard Medical School, Boston, 02114, MA, USA.
    Psoriasis is an autoimmune inflammatory skin disease. In the past several decades, phototherapy has been widely used to treat stable psoriatic lesions, including trunk, scalp, arms and legs, and partial nail psoriasis. A variety of light/lasers with different mechanisms of action have been developed for psoriasis including ultraviolet B (UVB), psoralen ultraviolet A (PUVA), pulsed dye laser (PDL), photodynamic therapy (PDT), intense pulsed light (IPL), light-emitting diodes (LED), and so on. Read More

    Effect of secukinumab on quality of life and psoriasis-related symptoms: a comparative analysis versus ustekinumab from the CLEAR 52-week study.
    J Am Acad Dermatol 2017 Oct 21. Epub 2017 Oct 21.
    Icahn School of Medicine at Mount Sinai, New York, NY, United States.
    Background: Secukinumab has demonstrated greater sustained skin clearance versus ustekinumab through Week 52, greater improvement in symptoms and health-related quality of life (HRQOL), and comparable safety profile.

    Objective: To assess the impact of secukinumab versus ustekinumab on complete relief from psoriasis-related symptoms, time to HRQOL response, and cumulative benefit among patients with moderate-to-severe plaque psoriasis.

    Methods: Psoriasis-related pain, itching, and scaling and the Dermatology Life Quality Index (DLQI) were compared between treatments based on time to complete relief of symptoms and to DLQI response in the CLEAR trial. Read More

    PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.
    J Dermatolog Treat 2017 Nov 10:1-6. Epub 2017 Nov 10.
    a U.O. Dermatologia , Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico , Milan , Italy.
    Background: Few studies have compared the use of different biologics in a real-life setting in plaque psoriasis patients.

    Objective: To compare the efficacy of biologics in psoriasis/psoriatic arthritis patients.

    Methods: Patients treated with adalimumab, etanercept and ustekinumab for at least 16 weeks were included. Read More

    Persistency of Biologic Therapies for Plaque Psoriasis in 2 Large Community Practices.
    J Cutan Med Surg 2017 Oct 1:1203475417733957. Epub 2017 Oct 1.
    5 Probity Medical Research Inc., Waterloo, ON, Canada.
    Background: Biologics have transformed the management of moderate to severe psoriasis. The persistency of biologics lacks real-world data.

    Objectives: To quantify drug survival of infliximab (IFX), adalimumab (ADA), etanercept (ETA), and ustekinumab (UST) and to identify potential factors affecting drug survival. Read More

    Endothelial function is impaired in the cutaneous microcirculation of adults with psoriasis through reductions in nitric oxide-dependent vasodilation.
    Am J Physiol Heart Circ Physiol 2017 Oct 20:ajpheart.00446.2017. Epub 2017 Oct 20.
    The Pennsylvania State University.
    Psoriasis is an independent risk factor for cardiovascular disease, however the underlying mechanisms are not fully understood. Deficits in conduit arterial function are evident in psoriatics, but potential impairments in microcirculatory endothelial function remain unclear. We hypothesized that cutaneous microvascular dysfunction would be detectable in otherwise healthy psoriatics. Read More

    Microbe-dependent induction of IL-9 by CLA(+) T cells in psoriasis and relationship with IL-17A.
    J Invest Dermatol 2017 Oct 17. Epub 2017 Oct 17.
    Translational Immunology, Department of Cellular Biology, Physiology and Immunology, Faculty of Biology, Universitat de Barcelona, Spain. Electronic address:
    IL-9 is present in psoriatic lesions and produced by lymphocytes. However, it is not known whether this cytokine is induced by relevant pathogenic triggers of psoriasis, such as Streptococcus pyogenes. Here we addressed the production of IL-9 in response to various pathogens in a psoriatic ex vivo model. Read More

    Superiority of a vitamin B12-containing emollient compared to a standard emollient in the maintenance treatment of mild-to-moderate plaque psoriasis.
    Int J Immunopathol Pharmacol 2017 Oct 1:394632017736674. Epub 2017 Oct 1.
    3 Dermatology, Department of Health Sciences, University 'Magna Græcia' of Catanzaro, Catanzaro, Italy.
    Psoriasis is a chronic inflammatory skin disease affecting 2%-3% of the population. The wide range of drugs currently available for its treatment could be associated, in the long term, with organ toxicity and adverse events, thus, clinical monitoring throughout treatment is required. This investigator-initiated trial (IIT) evaluated the efficacy and the safety of a vitamin B12-containing ointment in comparison with glycerol-petrolatum-based emollient cream used twice a day to treat mild-to-moderate plaque psoriasis for a period over 12 weeks followed by a wash-out observation period of 4 weeks. Read More

    Methotrexate treatment in a case of juvenile pityriasis rubra pilaris.
    Pediatr Dermatol 2017 Oct 17. Epub 2017 Oct 17.
    Department of Pediatric Dermatology, University of Minnesota, Minneapolis, MN, USA.
    An 8-year-old boy who was initially diagnosed with plaque psoriasis failed management with topical therapies and skin biopsy confirmed the suspected diagnosis of juvenile pityriasis rubra pilaris (PRP). Pityriasis rubra pilaris is a rare inflammatory disorder of the skin characterized by follicular keratotic papules coalescing into plaques, along with palmoplantar keratoderma. Treatment modalities include topical and systemic therapies, although previous studies have not shown much benefit with methotrexate in children. Read More

    Cost-Effectiveness Analysis of Ixekizumab vs Etanercept and Their Manufacturer-Recommended Dosing Regimens in Moderate to Severe Plaque Psoriasis.
    J Drugs Dermatol 2017 Oct;16(10):964-970
    Introduction: Biologic therapies have revolutionized the treatment of psoriasis; however, their use is limited by costs. Ixekizumab was more effective than etanercept in the UNCOVER trials, and the Food and Drug Administration (FDA) approved ixekizumab for treating psoriasis. Evaluating the cost-effectiveness of these therapies is crucial for medical decision making and our objective was to determine the cost-effectiveness of various ixekizumab dosing frequencies compared with etanercept. Read More

    Apremilast and Narrowband Ultraviolet-B Combination Therapy for Treating Moderate-to-Severe Plaque Psoriasis.
    J Drugs Dermatol 2017 Oct;16(10):957-962
    Background: Combining narrowband UVB (NB-UVB) phototherapy with biologics has been shown to enhance the therapeutic response of plaque psoriasis patients. The objective of this study was to evaluate the effectiveness of apremilast combined with NB-UVB in patients with moderate to severe plaque psoriasis.

    Methods: This was a 12-week, open-label study of 29 patients diagnosed with moderate to severe psoriasis. Read More

    Itolizumab - A New Biologic for Management of Psoriasis and Psoriatic Arthritis.
    Case Rep Dermatol 2017 May-Aug;9(2):141-145. Epub 2017 Aug 23.
    Derma-Care Skin and Cosmetology Centre, Mangalore, India.
    Psoriasis is a chronic, relapsing, inflammatory, immune-mediated systemic disease with mainly skin and joint manifestations. The available treatment options to cure psoriasis include topical therapy, phototherapy, and biological therapy. Biological therapy has become a promising option due to the rapid action and less adverse effects associated with its use. Read More

    Recurrence of Melanoma after Starting Apremilast for Psoriasis.
    Case Rep Dermatol 2017 May-Aug;9(2):108-111. Epub 2017 Aug 3.
    Division of Dermatology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
    This is a report on a 32-year-old man with a history of two previous melanomas with concurrent plaque-type psoriasis. His history dates to 2009, when he was diagnosed with his first melanoma on the right occiput, Clark's level IV, tumor thickness 1.53 mm, nonulcerated, mitotic index 1/mm(2). Read More

    An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target.
    Sci Transl Med 2017 Oct;9(411)
    Division of Genetics and Molecular Medicine, King's College London, London SE1 9RT, UK.
    Interleukin (IL)-36α, IL-36β, and IL-36γ are innate mediators of acute epithelial inflammation. We sought to demonstrate that these cytokines are also required for the pathogenesis of plaque psoriasis, a common and chronic skin disorder, caused by abnormal T helper 17 (TH17) cell activation. To investigate this possibility, we first defined the genes that are induced by IL-36 cytokines in primary human keratinocytes. Read More

    Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
    J Am Acad Dermatol 2017 Oct 6. Epub 2017 Oct 6.
    Oregon Health and Science University Hospital, Portland, Oregon.
    Background: Previous clinical trials have not evaluated improvement in nail psoriasis as a primary end point.

    Objective: This phase 3 trial evaluated the safety and efficacy of adalimumab in patients with moderate-to-severe fingernail psoriasis and moderate-to-severe plaque psoriasis.

    Methods: Patients were randomized 1:1 to 40 mg adalimumab every other week or placebo. Read More

    A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: a Canadian multicenter retrospective study.
    J Am Acad Dermatol 2017 Oct 5. Epub 2017 Oct 5.
    Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Women's College Hospital, Toronto, ON, Canada; Probity Medical Research Inc, Waterloo, ON, Canada.

    Metabolic parameters in psoriatic patients treated with interleukin-12/23 blockade (ustekinumab).
    J Dermatol 2017 Oct 5. Epub 2017 Oct 5.
    Department of Dermatology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan.
    The associations between psoriasis, metabolic syndrome and cardiovascular events are increasingly recognized. Studies have shown decreased cardiovascular events with the treatment of methotrexate and anti-tumor necrosis factor, however, effects of interleukin (IL)-12/23 blockade remain debatable. Our study investigated the effect of IL-12/23 blockade on the metabolic parameters in patients with psoriasis. Read More

    Association of Metabolic Syndrome in Chronic Plaque Psoriasis Patients and their Correlation with Disease Severity, Duration and Age: A Case Control Study from Western Maharashtra.
    J Clin Diagn Res 2017 Aug 1;11(8):WC06-WC10. Epub 2017 Aug 1.
    Professor, Department of Skin and V.D., B.J.G.M.C. and Sassoon General Hospital, Pune, Maharashtra, India.
    Introduction: Psoriasis is a chronic systemic inflammatory disease where the skin and the joints are the primary targets. Despite the fact that psoriasis carries minimal risk of mortality, it is associated with significant morbidity which may have a significant impact on quality of life of patients. Globally, psoriasis has been reported to be associated with Metabolic Syndrome (MS) including obesity, dyslipidemia, diabetes and hypertension. Read More

    Highlighting Interleukin-36 Signalling in Plaque Psoriasis and Pustular Psoriasis.
    Acta Derm Venereol 2017 Oct 2. Epub 2017 Oct 2.
    Department of Dermatology, Kyushu University, Maidashi 3-1-1, Higashiku, Fukuoka, 812-8582, Japan.
    Plaque psoriasis and pustular psoriasis are overlapping, but distinct, disorders. The therapeutic response to biologics supports the pivotal role of the tumour necrosis alpha (TNF-α)/ interleukin (IL)-23/IL-17/IL-22 axis in the pathogenesis of these disorders. Recently, functional activation of the IL-36 receptor (IL-36R) was discovered to be another driving force in the pathogenesis of psoriasis. Read More

    Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis.
    Value Health 2017 Sep 16;20(8):1174-1179. Epub 2017 Jun 16.
    University of Connecticut, Mansfield, CT, USA, and Probity Medical Research, Waterloo, Ontario, Canada.
    Objectives: The Psoriasis Symptom Inventory (PSI) is a patient-reported outcome instrument that measures the severity of psoriasis signs and symptoms. This study evaluated measurement properties of the PSI in patients with moderate to severe plaque psoriasis.

    Methods: This secondary analysis used pooled data from a phase 3 brodalumab clinical trial (AMAGINE-1). Read More

    Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.
    J Eur Acad Dermatol Venereol 2017 Sep 28. Epub 2017 Sep 28.
    Global Clinical Development, Biopharmaceuticals, Hexal AG, Holzkirchen, Germany.
    Background: EGALITY was a phase III confirmatory efficacy and safety study conducted in patients with plaque-type psoriasis as a part of totality of evidence gathered during the development of GP2015, an etanercept biosimilar.

    Objective: To demonstrate equivalent efficacy and comparable safety and immunogenicity of GP2015 and the etanercept originator product (ETN, Enbrel(®) ) and evaluate effects of repeated switching between GP2015 and ETN. Results for efficacy, safety and immunogenicity during treatment period (TP) 2 (TP2) are presented pooling the two continued treatment arms (pooled continued) versus the two treatment arms with repeated switches (pooled switched). Read More

    Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study.
    J Eur Acad Dermatol Venereol 2017 Sep 28. Epub 2017 Sep 28.
    German Center for Health Services Research in Dermatology (CVderm), Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
    Background: Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has demonstrated efficacy and safety in patients with moderate to severe psoriasis. However, as per study protocols, transition periods from prior psoriasis treatments of a defined minimal length were required and use of concomitant psoriasis medication was prohibited. There is therefore a lack of data on the effect of shorter transition periods and concomitant psoriasis treatment with other pharmacologically active substances on the effectiveness and safety of secukinumab in routine clinical practice. Read More

    Lymphopenia and CD4+/CD8+ Cell Reduction under Fumaric Acid Esters.
    Dermatology 2017 Sep 28. Epub 2017 Sep 28.
    Department of Dermatology, Venereology, and Allergology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
    Background: Fumaric acid esters (FAEs) are a broadly used therapy option for patients suffering from moderate-to-severe plaque psoriasis. Various studies in psoriasis have already shown peripheral blood lymphopenia during oral FAE therapy. Smaller studies also documented a reduction of CD4+ and CD8+ cell counts. Read More

    1 OF 71